3rd Sep 2018 07:00
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Half Year Results
Gaithersburg, MD - 03 September 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, will announce its interim results for the six months ended 30 June 2018 on Monday 24 September 2018.
Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call for analysts at 11:00 BST on the day of the results at the offices of Panmure Gordon, 1 New Change, London EC4M 9AF.
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com.
###
For further information, please contact:
MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer
| +1 301 944 1660 |
Nominated Adviser and Broker Panmure Gordon Emma Earl Freddy Crossley Ryan McCarthy Corporate Broking James Stearns
|
+44 (0)20 7886 2500 |
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Sukaina Virji |
+44 (0)203 709 5700 |
Related Shares:
MaxCyte